New combo therapy shows promise for tough bladder cancer cases

NCT ID NCT04610671

Completed Disease control Sponsor: H. Lee Moffitt Cancer Center and Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-stage study tested a combination of two drugs—CG0070 (a virus that targets cancer cells) and nivolumab (an immunotherapy that boosts the immune system)—in 21 people with muscle-invasive bladder cancer who were not eligible for standard chemotherapy. The goal was to see if the combination was safe and could help shrink tumors before surgery. The trial has been completed, but results are not yet widely available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CG0070 (a virus-based therapy) and nivolumab (an immunotherapy drug)
What this could lead to: If successful, this combination could offer a new treatment option for bladder cancer patients who cannot take standard chemotherapy.
What could go wrong: This is a very early (Phase 1) and small study (21 people), so results may not apply to everyone. Side effects from the drugs could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infiltrating bladder urothelial carcinoma urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER CANCER MUSCLE INVASIVE BLADDER CARCINOMA

Contacts and locations

Locations

Moffitt Cancer Center

Tampa, Florida, 33612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.